Trial finds Zanidatamab + chemo beneficial in HER2-positive gastroesophageal cancer
by Elana Gotkine edited by Stephanie Baum, reviewed by Andrew Zinin Editors’ notes The GIST Add as preferred source For patients with human epidermal growth factor receptor 2-positive (HER2-positive) metastatic or locally advanced unresected gastroesophageal adenocarcinoma (mGEA), zanidatamab and chemotherapy, with or without tislelizumab, may prolong survival compared with trastuzumab + chemotherapy, according to a study presented […]
Trial finds Zanidatamab + chemo beneficial in HER2-positive gastroesophageal cancer Read More »
